Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesImmutep Ltd

Immutep Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.021 AUD 0.00(0%)
Last update at 2026-11-06T05:10:00Z
VOLUME
6509569
Market Cap
30.95M

Momentum Score

…

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma. In addition, the company develops INSIGHT-003, which is in a Phase I trial for 1L non squamous non-small cell lung cancer (NSCLC); EOC 202, which has completed a Phase I trial for metastatic breast cancer; IMP761, an agonist LAG-3 antibody in a Phase I trial; IMP731, a LAG-3 depleting antibody that has completed a Phase II trial for ulcerative colitis and a Phase I trial for psoriasis; and ieramilimab/LAG525/IMP701, which are anti-LAG-3 antagonist antibodies. It has collaborations with Merck & Co., Inc., Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, the Maria Sklodowska-Curie National Research Institute of Oncology, EOC Pharma, Dr Reddy's Laboratories, Monash University, and George Washington University. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.02
Low
0.02
High
52 Week Price Range
0.02
Low
0.47
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Immutep Ltd is an Australia-based biotechnology company developing therapies that target the LAG‑3 immune checkpoint for cancer and autoimmune diseases. Long-term growth drivers include clinical progress, regulatory approvals, and potential commercialization or licensing of its LAG‑3 platform within the expanding immunotherapy market; investors may find it attractive because LAG‑3 is a validated target and clinical milestones could enable partnerships or future revenue.

Primary investment risks are high clinical and regulatory failure, limited current revenues with attendant financing and dilution risk, and intense competition and scientific uncertainty in immuno-oncology.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.02
Dividend Yield
-
Revenue TTM
19.93M
Revenue Per Share
0.01
Gross Profit TTM
-72.01M
Debt / Equity
0.02
ROE
-77.31%
Net Debt
-67.83M
ROCE
-121.38%
Diluted EPS TTM
-0.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -79.30M -61.43M -42.72M -39.90M -32.21M
Net income -79.30M -61.43M -42.72M -39.90M -32.21M
Selling general administrative - 8.64M 8.85M 8.68M 7.21M
Gross profit 12.08M -56.37M -37.70M - 0.17M
Reconciled depreciation - - - - 3.00M
Ebit -83.88M -65.01M -46.56M -41.43M -33.94M
Ebitda -81.41M -62.88M -44.54M - -31.87M
Depreciation and amortization 2.47M 2.13M 2.01M - 2.06M
Operating income -83.88M -126.42M -88.10M -40.63M -33.94M
Other operating expenses 98.44M 131.47M 91.95M - 34.01M
Interest expense 0.07M 0.04M 0.03M 0.02M 0.09M
Tax provision - - 0.00M 0.00M 0.00M
Interest income - 3.73M 3.88M 0.74M 0.33M
Net interest income - - 3.85M 0.92M 0.19M
Income tax expense - - - - 0.00M
Total revenue 14.56M 5.04M 3.84M 1.13M 0.17M
Total operating expenses 95.96M 70.06M 50.40M 41.43M 34.01M
Cost of revenue 2.47M 61.41M 41.55M - -
Total other income expense net 4.57M 64.99M 45.39M 0.62M 1.73M
Net income from continuing ops - - -42.72M -39.90M -46.82M
Net income applicable to common shares - -61.43M -42.72M -39.90M -32.21M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 83.27M 156.98M 201.58M 147.45M 102.17M
Intangible assets 1.38M 7.09M 8.13M 9.38M 10.44M
Other current assets 2.13M 19.40M - 0.05M 3.55M
Total liab 21.73M 13.35M 12.06M 10.98M 8.09M
Total stockholder equity 61.53M 143.64M 189.52M 136.47M 94.08M
Other current liab 7.98M 5.91M - 4.14M 3.37M
Common stock 547.65M 535.07M - 446.27M 367.41M
Capital stock - - 542.11M 446.27M 534.09M
Retained earnings -520.80M -444.08M -382.65M -339.93M -302.34M
Other liab - - - 0.16M 0.12M
Good will 0.11M 0.11M 0.11M 0.11M 0.11M
Other assets - - - 2.52M 0.50M
Cash 68.87M 67.41M 161.79M 123.42M 80.00M
Cash and equivalents - - - 3.59M 0.30M
Total current liabilities 14.16M 12.76M 10.49M 9.77M 6.41M
Net debt -67.83M -65.78M - -122.19M -78.26M
Short term debt 0.29M 1.31M - 0.19M 0.17M
Short long term debt total 1.05M 1.63M - 1.23M 1.73M
Other stockholder equity - - - 6.43M 5.43M
Property plant equipment - - - 0.47M 0.31M
Total current assets 80.63M 149.10M 191.35M 134.97M 90.81M
Net tangible assets - - - 126.98M 83.52M
Short term investments - 62.28M 20.09M - -
Net receivables 9.62M 0.01M 0.01M 7.97M 8.37M
Long term debt - - 0.96M 0.84M 2.11M
Inventory - - - - -1.11M
Accounts payable 5.89M 5.53M 3.79M 5.45M 2.87M
Accumulated other comprehensive income 34.68M 52.65M - 30.13M 29.00M
Non currrent assets other 0.05M 0.12M - 2.52M 0.50M
Non current assets total 2.64M 7.89M 10.23M 12.48M 11.36M
Capital lease obligations - - 0.63M 0.39M 0.41M
Long term debt total - - - 1.04M 1.56M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - -21.02M -0.03M -0.04M
Change to liabilities - - - 3.27M 1.44M
Total cashflows from investing activities 56.46M -38.53M -21.02M -0.08M -0.02M
Net borrowings - - -0.23M -0.21M -0.22M
Total cash from financing activities -0.21M -0.53M 95.18M 76.04M 50.33M
Change to operating activities - - - -0.90M -0.75M
Net income -79.30M -61.43M -42.72M -39.90M -32.21M
Change in cash 1.46M -94.38M 38.37M 43.42M 19.40M
Begin period cash flow 67.41M 161.79M 123.42M 80.00M 60.59M
End period cash flow 68.87M 67.41M 161.79M 123.42M 80.00M
Total cash from operating activities -55.46M -62.05M -34.82M -35.88M -30.23M
Issuance of capital stock - - 100.24M 80.08M 52.98M
Depreciation 2.47M 2.39M - 2.06M 2.06M
Other cashflows from investing activities -0.03M -0.23M -0.90M - -
Dividends paid - - - 0.00M 0.00M
Change to account receivables 0.46M -2.52M 0.60M -1.61M -2.25M
Sale purchase of stock - - - 80.08M 52.98M
Other cashflows from financing activities -0.21M - -4.83M -3.86M -2.43M
Change to netincome - - - 1.71M 1.48M
Capital expenditures 0.09M 0.05M 0.93M 0.05M 0.02M
Change in working capital 16.59M -8.54M 3.99M 4.66M -1.56M
Stock based compensation - 1.16M - - 1.49M
Other non cash items 4.78M 4.37M -38.82M - -0.01M
Free cash flow -55.56M -62.10M -35.75M -35.93M -30.25M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IMM
Immutep Ltd		 -
-%		 0.02 - 7.20 1.55 0.50 0.10 -4.42
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Immutep Ltd

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma. In addition, the company develops INSIGHT-003, which is in a Phase I trial for 1L non squamous non-small cell lung cancer (NSCLC); EOC 202, which has completed a Phase I trial for metastatic breast cancer; IMP761, an agonist LAG-3 antibody in a Phase I trial; IMP731, a LAG-3 depleting antibody that has completed a Phase II trial for ulcerative colitis and a Phase I trial for psoriasis; and ieramilimab/LAG525/IMP701, which are anti-LAG-3 antagonist antibodies. It has collaborations with Merck & Co., Inc., Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, the Maria Sklodowska-Curie National Research Institute of Oncology, EOC Pharma, Dr Reddy's Laboratories, Monash University, and George Washington University. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Australia Square, Sydney, NSW, Australia, 2000

61 2 8315 7003

https://www.immutep.com

Name Title Year Born
Mr. Marc Voigt CEO, MD, CFO, Chief Bus. Officer & Exec. Director 1973
Ms. Deanne Miller LLB COO, Gen. Counsel & Joint Company Sec. 1977
Dr. Frederic Triebel M.D., Ph.D. Chief Scientific Officer, Chief Medical Officer & Exec. Director 1955
Ms. Indira Naidu Joint Company Sec. NA
Mr. Christian Mueller Director of Clinical Devel. & Regulatory Affairs NA
Mr. Shengfei Fang Fin. Director & Assistant Company Sec. NA
Mr. Marc Voigt CEO, MD, CFO, Chief Business Officer & Executive Director 1973
Ms. Deanne Miller LLB COO, General Counsel & Joint Company Secretary 1977
Dr. Frederic Triebel M.D., Ph.D. Chief Scientific Officer & Executive Director 1955
Mr. Marc Voigt CEO, MD, CFO, Chief Business Officer & Executive Director 1973

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…